Holen Sie sich die Stockscreener-App
0.5251
5.42%
-0.0301
Schlusskurs vom Vortag:
$0.5552
Offen:
$0.54
24-Stunden-Volumen:
228.93K
Relative Volume:
0.46
Marktkapitalisierung:
$6.36M
Einnahmen:
$1.84M
Nettoeinkommen (Verlust:
$-17.51M
KGV:
-0.3792
EPS:
-1.3849
Netto-Cashflow:
$-17.30M
1W Leistung:
-11.15%
1M Leistung:
-24.97%
6M Leistung:
-46.87%
1J Leistung:
-66.77%
1-Tages-Spanne:
$0.51
$0.5576
1-Wochen-Bereich:
$0.51
$0.60
52-Wochen-Spanne:
$0.51
$1.57
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.5251 | 6.36M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-07-29 | Eingeleitet | Aegis Capital | Buy |
| 2020-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Eingeleitet | Oppenheimer | Outperform |
Evogene Ltd Aktie (EVGN) Neueste Nachrichten
Evogene StockWeekly review and sector context after recent Q1 update - AD HOC NEWS
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene Ltd (EVGN) Institutional Confidence - TradingKey
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene Ltd (EVGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVGN Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Weak Operating PerformancePretax Income Report - newsline.com
Evogene Showcases AI-Driven ChemPass Platform and Expanded Google Cloud Collaboration in New Investor Deck - TipRanks
Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy - Stock Titan
EVGN Q1 2026 Earnings: Deep EPS Miss Raises Investor Concerns Amid Pre-Revenue StageTrough Earnings Signal - newsline.com
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Franc - GuruFocus
Evogene Shares Slip 2.6% as Biotech Stock Tests Key Support Level (EVGN)Flat Correction - newsline.com
Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P. - The Globe and Mail
Evogene enters sales agreement for at-the-market offering of up to $2.93 million - Investing.com Australia
Evogene Ltd. (NASDAQ: EVGN) launches $2.93M ATM program with A.G.P. - Stock Titan
Evogene (EVGN) launches $2.93M at-the-market share offering with A.G.P. - Stock Titan
EVGN Q1 2026 Earnings: Significant EPS Miss Amid Ongoing Operational ChallengesBasic EPS Analysis - newsline.com
Evogene Q1 revenue falls to $0.3 million amid strategic shift - scanx.trade
Full Transcript: Evogene Q1 2026 Earnings Call - Benzinga
Inside Evogene’s AI drug hunt: ChemPass platform hits BIO 2026 stage - Stock Titan
Evogene to Present Its Pharma Division Achievements at the BIO International Convention - PR Newswire
Earnings Call Summary | Evogene(EVGN.US) Q1 2026 Earnings Conference - 富途牛牛
EVGN Stock Price, Quote & Chart | EVOGENE LTD (NASDAQ:EVGN) - ChartMill
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
EVGN Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesProfit Warning Alert - newsline.com
Evogene completes phase 1 trial of BMC128 cancer treatment By Investing.com - Investing.com South Africa
Evogene: Q1 Earnings Snapshot - AOL.com
Evogene (EVGN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Evogene says Phase 1 clinical study of BMC128 met primary endpoint - TipRanks
Evogene completes phase 1 trial of BMC128 cancer treatment - Investing.com
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica - PR Newswire
Evogene Ltd stock (IL0010831684): Shares trade quietly as investors await next catalysts - AD HOC NEWS
Evogene (EVGN) Edges Lower, Testing Key Support at $0.66Dealer Delta - newsline.com
Evogene Ltd (EVGN) Holding Near Support After Modest DeclineFibonacci Arc - The Legal Advocate
EVGN Q1 2026 Earnings: Significant EPS Miss Highlights Operational ChallengesShare Repurchase Impact - The Legal Advocate
Evogene Back Under $1 as Nasdaq Deadline Approaches - Bez Kabli
Evogene (EVGN) Edges Higher: Modest Uptick Amid Support Level TestFactor Crowding - The Legal Advocate
Evogene Ltd (EVGN) Q1 2026 Earnings Call Highlights: Strategic Collaborations Amid Financial ... By GuruFocus - Investing.com Canada
EVGN - Finviz
Evogene (EVGN) Slides 3% as Shares Test Key Support Near $0.66Put Wall - newsline.com
A. G. P. Maintains Evogene(EVGN.US) With Buy Rating, Cuts Target Price to $2.15 - Moomoo
Evogene shares decline after revenue miss despite stronger-than-expected earnings (EVGN) - MSN
Evogene Q1 2026 earnings preview - MSN
Evogene Ltd. (NASDAQ:EVGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Evogene reports Q1 2026 loss, stock rises 1.95% By Investing.com - Investing.com South Africa
Evogene Tightens Focus on AI Small-Molecule Platform as Q1 2026 Revenue Falls - The Globe and Mail
Evogene Reports First Quarter 2026 Financial Results - Global Agriculture
Finanzdaten der Evogene Ltd-Aktie (EVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):